Verona Pharma PLC American Depositary Share (VRNA) Stock Forecast & Price Target

$91.18 +1.10 (+1.22%)

Closing price 07/3/2025 03:13 PM Eastern

Extended Trading

$91.42 +0.24 (+0.26%)

As of 07/3/2025 04:58 PM Eastern

Verona Pharma PLC American Depositary Share - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 12 Analyst Ratings

Sell
0

Hold
0

Buy
12

Based on 12 Wall Street analysts who have issued ratings for Verona Pharma PLC American Depositary Share in the last 12 months, the stock has a consensus rating of "Buy." Out of the 12 analysts, 12 have given a buy rating for VRNA.

Consensus Price Target

$107.36
17.75% Upside

According to the 12 analysts' twelve-month price targets for Verona Pharma PLC American Depositary Share, the average price target is $107.36. The highest price target for VRNA is $170.00, while the lowest price target for VRNA is $57.00. The average price target represents a forecasted upside of 17.75% from the current price of $91.18.

Get the Latest News and Ratings for VRNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and its competitors.

VRNA Analyst Ratings Over Time

Type	Current Forecast 7/4/24 to 7/4/25	1 Month Ago 6/4/24 to 6/4/25	3 Months Ago 4/5/24 to 4/5/25	1 Year Ago 7/5/23 to 7/4/24
Strong Buy	0 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$107.36	$82.13	$69.14	$35.60
Forecasted Upside	17.75% Upside	-2.21% Downside	28.28% Upside	126.61% Upside
Consensus Rating	Buy	Buy	Buy	Buy

VRNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

VRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Verona Pharma PLC American Depositary Share Stock vs. The Competition

Type	Verona Pharma PLC American Depositary Share	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.53
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	17.75% Upside	8,522.19% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent VRNA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/1/2025	Wolfe Research 4 of 5 stars	Andy Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$170.00	+79.74%
6/23/2025	Piper Sandler 2 of 5 stars	Yasmeen Rahimi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target	Overweight ➝ Overweight	$76.00 ➝ $160.00	+67.33%
6/20/2025	Wells Fargo & Company 3 of 5 stars	Tiago Fauth Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$107.00 ➝ $138.00	+51.78%
6/18/2025	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Pachaiyappan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$92.00 ➝ $116.00	+26.68%
6/11/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	O. Brayer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$90.00 ➝ $100.00	+10.10%
6/11/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Andrew Tsai Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$95.00 ➝ $110.00	+21.11%
6/2/2025	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Raghuram Selvaraju Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$85.00 ➝ $90.00	+11.34%
4/28/2025	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy
4/28/2025	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Bancroft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$100.00	+52.77%
2/12/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Edward Nash Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$44.00 ➝ $72.00	+21.36%
Get the Latest News and Ratings for VRNA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and its competitors with MarketBeat's FREE daily newsletter.
1/10/2025	Roth Mkm Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boobalan Pachaiyappan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$68.00	+47.19%
1/8/2025	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$44.00 ➝ $57.00	+18.75%
3/1/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$33.00	+91.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 03:14 AM ET.

VRNA Forecast - Frequently Asked Questions

: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Verona Pharma PLC American Depositary Share is $107.36, with a high forecast of $170.00 and a low forecast of $57.00.
: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma PLC American Depositary Share in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VRNA shares.
: According to analysts, Verona Pharma PLC American Depositary Share's stock has a predicted upside of 17.75% based on their 12-month stock forecasts.
: Verona Pharma PLC American Depositary Share has been rated by research analysts at Cantor Fitzgerald, Cowen, HC Wainwright, Jefferies Financial Group, Piper Sandler, Roth Capital, TD Cowen, Wells Fargo & Company, and Wolfe Research in the past 90 days.
: Analysts like Verona Pharma PLC American Depositary Share more than other "medical" companies. The consensus rating for Verona Pharma PLC American Depositary Share is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how VRNA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:VRNA) was last updated on 7/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Verona Pharma PLC American Depositary Share (VRNA) Stock Forecast & Price Target